Details of the Drug

General Information of Drug (ID: DMOHS9P)

Drug Name

Phenacemide

Synonyms

Acetylureum; Carbanmide; Cetylureum; Comitiadone; Eferon; Efron; Epheron; Epiclase; Felurea; Fenacemid; Fenacemida; Fenacemide;Fenacetamide; Fenilep; Fenised; Fenostenyl; Fenural; Fenurea; Fenurone; Fenylacetylmocovina; Fenytan; Neophedan; Neophenal; Phacetur; Phenacalum; Phenacemidum; Phenacereum; Phenacerum; Phenacetur; Phenacetylcarbamide; Phenacetylurea; Phenarone; Phenicarb; Phenuron; Phenurone; Phenutal; Phenylacetylurea; Phenylacetyluree; Phenyrit; Phetylureum; Carbamide phenylacetate; Fenacemide [DCIT]; Fenylacetylmocovina [Czech]; Phenylacetyluree [French]; A-1348; Alpha-Phenylacetylurea; Fenacemida [INN-Spanish]; Fenacetil-karbamide; Phenacemide [INN:BAN]; Phenacemidum [INN-Latin]; Phenurone (TN); Sym-PHENYLACETYLUREA; N-(Aminocarbonyl)benzeneacetamide; Phenacemide (JAN/INN); N-carbamoyl-2-phenylacetamide; N-(aminocarbonyl)-2-phenylacetamide; (2-phenylacetyl)urea; (Phenylacetyl)urea

Indication

Disease Entry	ICD 11	Status	REF
Epilepsy	8A60-8A68	Approved	[1], [2]

Therapeutic Class

Anticonvulsants

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

178.19

Topological Polar Surface Area (xlogp)

0.9

Rotatable Bond Count (rotbonds)

2

Hydrogen Bond Donor Count (hbonddonor)

2

Hydrogen Bond Acceptor Count (hbondacc)

2

ADMET Property

Absorption: The drug is almost completely absorbed [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 22 - 25 hours [4]
Metabolism: The drug is metabolized via the liver [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 280.59583 micromolar/kg/day [5]

Chemical Identifiers

Formula: C9H10N2O2
IUPAC Name: N-carbamoyl-2-phenylacetamide
Canonical SMILES: C1=CC=C(C=C1)CC(=O)NC(=O)N
InChI: InChI=1S/C9H10N2O2/c10-9(13)11-8(12)6-7-4-2-1-3-5-7/h1-5H,6H2,(H3,10,11,12,13)
InChIKey: XPFRXWCVYUEORT-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4753
ChEBI ID: CHEBI:8049
CAS Number: 63-98-9
DrugBank ID: DB01121
TTD ID: D07ONP

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sodium channel unspecific (NaC)	TTRK8B9	NOUNIPROTAC	Blocker	[6]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Phenacemide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Levomilnacipran	DMV26S8	Moderate	Antagonize the effect of Phenacemide when combined with Levomilnacipran.	Chronic pain [MG30]	[17]
Vilazodone	DM4LECQ	Moderate	Antagonize the effect of Phenacemide when combined with Vilazodone.	Depression [6A70-6A7Z]	[17]
Vortioxetine	DM6F1PU	Moderate	Antagonize the effect of Phenacemide when combined with Vortioxetine.	Depression [6A70-6A7Z]	[17]
Milnacipran	DMBFE74	Moderate	Antagonize the effect of Phenacemide when combined with Milnacipran.	Depression [6A70-6A7Z]	[17]
Escitalopram	DMFK9HG	Moderate	Antagonize the effect of Phenacemide when combined with Escitalopram.	Depression [6A70-6A7Z]	[17]
Desvenlafaxine	DMHD4PE	Moderate	Antagonize the effect of Phenacemide when combined with Desvenlafaxine.	Depression [6A70-6A7Z]	[17]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Phenacemide and Esketamine.	Depression [6A70-6A7Z]	[18]
Hydroxychloroquine	DMSIVND	Moderate	Antagonize the effect of Phenacemide when combined with Hydroxychloroquine.	Malaria [1F40-1F45]	[18]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Phenacemide and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[19]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Phenacemide and Lasmiditan.	Migraine [8A80]	[20]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Phenacemide and Flibanserin.	Mood disorder [6A60-6E23]	[21]
-----------


⏷ Show the Full List of 11 DDI Information of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7265).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 007707.
3	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7	Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
8	Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7.
9	Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8.
10	Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
11	Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
12	Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
13	Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
14	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
15	In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8.
16	Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
17	Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
18	Cerner Multum, Inc. "Australian Product Information.".
19	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
20	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
21	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.